https://www.selleckchem.com/pr....oducts/cyclophospham
The objective of this study was to assess incremental costs and benefits of a human papillomavirus (HPV) vaccination program expanded to include "mid-adults" (adults aged 27 through 45years) in the United States. We adapted a previously published, dynamic mathematical model of HPV transmission and HPV-associated disease to estimate the incremental costs and benefits of a 9-valent HPV vaccine (9vHPV) program for people aged 12 through 45years compared to a 9vHPV program for females aged 12 through 26years and males a
Curtir
Comentario
Compartilhar
